In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The price of Xenon Pharmaceuticals Inc (NASDAQ: XENE) closed at $39.09 in the last session, down -4.94% from day before closing price of $41.12. In other words, the price has decreased by -$4.94 from its previous closing price. On the day, 1.44 million shares were traded. XENE stock price reached its highest trading level at $40.45 during the session, while it also had its lowest trading level at $37.625.
Ratios:
We take a closer look at XENE’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 12.52 and its Current Ratio is at 12.52. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
On May 07, 2025, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $55.
On February 11, 2025, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $67.Deutsche Bank initiated its Buy rating on February 11, 2025, with a $67 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 01 ’25 when MORTIMER IAN sold 25,000 shares for $40.16 per share. The transaction valued at 1,004,000 led to the insider holds 31,302 shares of the business.
IAN MORTIMER bought 25,000 shares of XENE for $1,004,117 on Oct 01 ’25. On Sep 19 ’25, another insider, SHERRY AULIN, who serves as the Former officer of the company, bought 2,548 shares for $37.08 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XENE now has a Market Capitalization of 3020680192 and an Enterprise Value of 2566738944. For the stock, the TTM Price-to-Sale (P/S) ratio is 401.88 while its Price-to-Book (P/B) ratio in mrq is 5.39. Its current Enterprise Value per Revenue stands at 342.232 whereas that against EBITDA is -7.59.
Stock Price History:
The Beta on a monthly basis for XENE is 1.04, which has changed by -0.08500224 over the last 52 weeks, in comparison to a change of 0.15566266 over the same period for the S&P500. Over the past 52 weeks, XENE has reached a high of $46.00, while it has fallen to a 52-week low of $26.74. The 50-Day Moving Average of the stock is -0.80%, while the 200-Day Moving Average is calculated to be 9.44%.
Shares Statistics:
According to the various share statistics, XENE traded on average about 830.42K shares per day over the past 3-months and 828420 shares per day over the past 10 days. A total of 77.12M shares are outstanding, with a floating share count of 74.02M. Insiders hold about 4.00% of the company’s shares, while institutions hold 104.23% stake in the company. Shares short for XENE as of 1760486400 were 6148669 with a Short Ratio of 7.40, compared to 1757894400 on 7040555. Therefore, it implies a Short% of Shares Outstanding of 6148669 and a Short% of Float of 8.89.
Earnings Estimates
. The current rating of Xenon Pharmaceuticals Inc (XENE) reflects the combined expertise of 10.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$1.14, with high estimates of -$0.96 and low estimates of -$1.33.
Analysts are recommending an EPS of between -$4.15 and -$4.33 for the fiscal current year, implying an average EPS of -$4.24. EPS for the following year is -$4.59, with 15.0 analysts recommending between -$2.15 and -$5.4.
